In vivo experiments confirmed that NOD mice treated with soluble BAFF receptor (BAFFR) and anti-CXCL13 antibody do not develop salivary dysfunction, and that blocking BAFFR attenuates SS disease progression and may be an effective therapeutic strategy for SS (121). The gene discussed is CXCL13; the disease is synovial sarcoma.